Purchase of Axiom Brain Health puts Tampa clinical trial site at center of research to find easier way to detect disease in patients. TAMPA — The most reliable way to to diagnose Alzheimer’s disease is through a positron emission tomography or PET scan of the brain, an expensive test not always covered by insurance. Another […]

His wife, Joann, is a retired nurse and also knew that research was going to be the way forward for them and for future generations.   To find out about studies near you, go to K2Med.com or Fastertrials.org to find sites around the US.

‘Coming in and just answer some questions, and seeing if there’s something that needs to be investigated,’ By: Victor Jorges WPTV5 DELRAY BEACH, Fla. — A Palm Beach County research organization is helping people with their memory for free. Brain Matters Research in Delray Beach is hosting free memory screenings on Tuesday and Wednesday from 9 […]

People with Down syndrome helped scientists pave the way for Alzheimer’s drugs but are now left out of the treatment. By Hampus Hillerstrom and Jo Ann Simons  The clinical trials for new Alzheimer’s disease treatment drugs — which researchers believe will slow the course of the disease over time — offer hope to thousands of […]

By Janet Lee – Washington Post Consumer Reports has no financial relationship with any advertisers on this site. Doing puzzles, playing memory-boosting games, taking classes and reading are activities that we often turn to for help keeping our brains sharp. But research is showing that what you eat, how often you exercise and the type of exercise you do […]

Free, bilingual screening on World Alzheimer’s Day Intercoastal Medical Group Neurology and Research Clinic will hold a free, bilingual?memory?screening event on World Alzheimer’s Day on Sept. 21 from 8 a.m. to 3 p.m. at Robert L. Taylor Community Complex, 1845 John Rivers St., in Sarasota. The goal of the confidential? screening in English and Spanish […]

By Cathy Kelly Medicare policymakers have felt that without an effective approved treatment, coverage of amyloid PET scans and APOE4 genetic tests was not warranted. But that is changing. There is more to Medicare coverage for Alzheimer’s treatment than Leqembi, Eisai Co., Ltd. and Biogen, Inc.’s newly-approved amyloid-targeting monoclonal antibody. Now the program also is considering amending restrictive coverage […]

By Cathy Kelly There is no fee to participate, and entries to the registry must be made at baseline and then every six months for up to two years. The Centers for Medicare and Medicaid Services is sticking with its plan to provide broader Medicare coverage for Eisai Co., Ltd. and Biogen, Inc.’s Leqembi for Alzheimer’s – now that […]

WASHINGTON, DC, May 3, 2023 — Following the announcement of Eli Lilly’s Phase 3 results on a study evaluating donanemab for the treatment of Alzheimer’s disease, Global Alzheimer’s Platform Foundation® (GAP) President John Dwyer said, “Today’s announcement is good news. After waiting nearly 20 years for a new treatment for Alzheimer’s, Alzheimer’s patients and their doctors […]

House Energy & Commerce Subcommittee Tells CMS: Fix Alzheimer’s Drug Coverage WASHINGTON, DC (April 27, 2023) – The Global Alzheimer’s Platform Foundation®(GAP) President John Dwyer commends the strong, bipartisan leadership shown yesterday by U.S. Reps. Brett Guthrie (R-KY) and Anna Eshoo (D-CA) for admonishing the U.S. Centers for Medicare and Medicaid Services (CMS) administrator Chiquita […]

by Barbara Campos – Telemundo According to the conclusions of a new Alzheimer’s Association report, Hispanics are almost twice as at risk as other demographic groups, and caring for patients can place a heavy burden on households. The report illustrates the need to allocate more resources and efforts to raise awareness about a degenerative disease […]

“GAP strongly encourages ICER to revamp its model to accurately reflect Leqembi’s benefits and what matters most to patients and their families” For immediate release: Washington, D.C. (March 17, 2023) — Joining other Alzheimer’s advocates, experts and researchers, Global Alzheimer’s Platform Foundation® (GAP) President John Dwyer provided written comments as part of the Institute for […]

“Today, the Veterans Health Administration (VA) demonstrated enormous leadership and concern for the health of veteran’s fighting Alzheimer’s disease with its decision to cover the cost of Leqembi.  Our veterans battled for us, and the VA is now giving their patients new therapies to battle Alzheimer’s.” Statement by Global Alzheimer’s Platform Foundation® President John Dwyer: […]

BAY VILLAGE, Ohio — There are two newly-approved treatments to treat Alzheimer’s Disease, but getting them covered by medicare is a battle. Alzheimer’s impacts nearly 6 million Americans over the age of 65, and that number is expected to triple by 2060. It is the sixth leading cause of death in the U.S., according to […]

Statement by Global Alzheimer’s Platform Foundation® President John Dwyer: Washington, D.C. (Feb. 27, 2023) — “On behalf of the of the thousands of trial participants, clinicians and researchers who are part of the Global Alzheimer’s Platform Foundation (GAP) network, we want to thank and honor Dr. Billy Dunn for his leadership and scientific contributions, which […]

“CMS’s latest decision on disease-modifying therapies for Alzheimer’s patients is effectively a coverage denial for this entire class of drugs, and patients will needlessly die as a result of it.” Statement by Global Alzheimer’s Platform Foundation® President John Dwyer: Washington, D.C. (Feb. 23, 2023) — “Once again, the Centers for Medicare and Medicaid Services (CMS) […]

The Global Alzheimer’s Platform Foundation’s® (GAP) 2022 Citizen Scientist Award recipients include the first husband-and-wife volunteer team, an Alzheimer’s advocate who champions participation in prevention studies, and a Parkinson’s disease clinical trial participant who volunteers in research studies to find hope after diagnosis  WASHINGTON, DC (Feb. 22, 2023) — Today, the Global Alzheimer’s Platform Foundation […]